FOR IMMEDIATE RELEASE
INFORM GENOMICS ANNOUNCES RESULTS OF STUDY PREDICTING RISK OF ORAL
MUCOSITIS IN PATIENTS UNDERGOING HIGH DOSE CHEMOTHERAPY
--Data to be presented at 2012 ASCO Annual Meeting---Collaboration agreement with Swedish Orphan Biovitrum established to further
develop and commercialize the personalized medicine product-Boston, MA- April 18, 2012- Inform Genomics, Inc., a private company focused on developing novel
platforms of personalized medicine products for cancer supportive care and inflammatory diseases,
today announced the completion of the first phase of product development to predict a patient’s risk
of developing oral mucositis after receiving high dose chemotherapy prior to hematopoietic stem cell
transplant. The results of this single center, 153-patient study demonstrated the product’s ability to
discriminate which patients develop oral mucositis with 99.3% accuracy and an area under the Receiver
Operator Characteristic (ROC) curve of 99.7%. Further development will include validation of these
initial results in a multicenter study. In addition, Inform Genomics announced that it entered into a
collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) to further develop and
commercialize the product. Sobi is a leading integrated biopharmaceutical company dedicated to
bringing innovative therapies and services to improve the health of rare disease patients and their
families.
“We are very pleased with the exciting results of this study,” said Ed Rubenstein, M.D., President &
CEO of Inform Genomics, “and our agreement with Sobi demonstrates the value our technology can
bring to biopharma partners while expanding the market opportunity for both companies’ products.
When commercialized, this product will be available for the hematology oncology stem cell transplant
market and will complement the target market of our lead product, OnPART™ for patients with solid
tumors.”
The principal investigator for the study, Stephen T. Sonis, D.M.D., D.M.Sc., Chief Scientific Officer of
Biomodels, LLC, who also serves as the Chief of the Division of Oral Medicine at the Dana-Farber Cancer
Institute and Professor of Oral Medicine at the Harvard School of Dental Medicine, will present the
results of the study at the upcoming 2012 American Society of Clinical Oncology (ASCO) Annual
Meeting, as part of the educational session titled “Mucosal Injury in Patients with Cancer: Targeting
the Biology,” taking place from 11:30 am to 12:45 pm on Sunday, June 3, 2012 in Chicago, IL.
About OnPART™
OnPART™, Oncology Preferences And Risk of Toxicity, will be Inform Genomics’ first platform
molecular diagnostic test for personalizing treatment decisions for patients undergoing chemotherapy
for colorectal, breast, lung or ovarian cancer. Based upon response rates and survival, more than one
chemotherapy regimen may be considered appropriate care for patients with these common solid
tumors, yet the regimens vary widely in their toxicity profiles, including nausea & vomiting, diarrhea,
oral mucositis, cognitive dysfunction, fatigue and peripheral neuropathy. OnPART™ is being developed
to assess genomic risk for these side effects, and to provide valuable information for patients and
medical oncologists to help clarify clinical choices.
101 Federal Street
Suite 1900
Boston, Massachusetts 02110
About Inform Genomics
Inform Genomics, Inc. is a private company focused on developing novel platforms of personalized
medicine products for cancer supportive care and inflammatory diseases, including its lead product,
OnPART™, designed to predict an individual’s risk of six common toxicities of commonly used
chemotherapy regimens based on his or her individual genomic profile. The Company’s business model
leverages existing technology in conjunction with proprietary analytic methods for conducting genomewide association studies. Product development programs will lead to commercial, single source
laboratory tests consisting of single-nucleotide polymorphism (SNP) clusters that determine the
likelihood of individual patient clinical outcomes to drug therapies. The U.S. market opportunity for
these differentiated products exceeds $2 billion annually. Inform Genomics is headquartered in Boston,
Massachusetts. For more information, please visit www.informgenomics.com.
Contact:
Bill Brown, Chief Financial Officer
bbrown@informgenomics.com
101 Federal Street
Suite 1900
Boston, Massachusetts 02110